Navigation Links
Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron

BILLERICA, Massachusetts --- June 20, 2007 --- Millipore Corporation today announced the release of new data concerning its ReNcell neural stem cell lines. The research was conducted by the Department of Physiology at University College London and ReNeuron Group plc, whose ReNcell distribution agreement with Millipore was announced in 2006. The data will be presented by Dr. Vi Chu, research & development scientist for Millipore’s Bioprocess Division, in a technology talk at the ISSCR meeting in Cairns, Australia on June 20, 2007.

The data conclude that the ReNcell lines, ReNcell VM and ReNcell CX, will continuously expand in monolayer culture. Both cell lines have the ability to differentiate into neurons, astrocytes and oligodendrocytes, and the researchers were able to differentiation the ReNcell VM line into electrophysiologically active dopaminergic neurons. The study was published in the May edition of BMC Neuroscience and may be read in its entirety at:

The ReNcell neural stem cell lines are immortalized human neural progenitor cells that have the ability to readily differentiate into neural cell types and will replicate indefinitely. ReNcell immortalized cells display the same marker patterns as normal cells and are able to grow and remain stable after culturing. These cells are important tools for the discovery of new therapies targeting diseases of the central nervous system.

Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon, Upstate and Linco product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit


About Millipore

Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are esse ntial for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at:

About ReNeuron Group plc

ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. The Group has also leveraged their stem cell technologies into non-therapeutic areas such as drug discovery. ReNeuron was founded in 1997 to commercialize technology discovered by its founding scientists working at the Institute of Psychiatry, Kings College London. ReNeuron currently employs around 30 staff, including 15PhDs, with many years combined experience in stem cell research and development. ReNeuron operates form state-of-the-art laboratories in Guildford, Surrey, UK, which are fitted out to meet the stringent requirements of the regulatory authorities for cell therapy products. For additional information on ReNeuron, please visit its website at:

Millipore is a registered trademark of Millipore Corporation. ReNcell is a registered trademark of ReNeuron Group plc.

Media Contact:

Lauren Nolan

Communications Specialist

Millipore Corporation



Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
3. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
4. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):